New Drugs, Therapeutic Strategies, and Future Direction for the Treatment of Pulmonary Arterial Hypertension

Curr Med Chem. 2019;26(16):2844-2864. doi: 10.2174/0929867325666180201095743.

Abstract

Despite recent advances in Pulmonary Arterial Hypertension (PAH) treatment, this condition is still characterized by an extremely poor prognosis. In this review, we discuss the use of newly-approved drugs for PAH treatment with already known mechanisms of action (macitentan), innovative targets (riociguat and selexipag), and novel therapeutic approaches with initial up-front combination therapy. Secondly, we describe new potential signaling pathways and investigational drugs with promising role in the treatment of PAH.

Keywords: Pulmonary arterial hypertension; gene therapy; immunity; inflammation; initial combination therapy; macitentan; metabolism; pulmonary arterial denervation; riociguat; selexipag; serotonin..

Publication types

  • Review

MeSH terms

  • Animals
  • Endothelin Receptor Antagonists / pharmacology
  • Genetic Therapy
  • Humans
  • Hypertension, Pulmonary / drug therapy
  • Hypertension, Pulmonary / therapy*
  • Immunotherapy
  • Phosphodiesterase 5 Inhibitors / pharmacology
  • Signal Transduction / drug effects*

Substances

  • Endothelin Receptor Antagonists
  • Phosphodiesterase 5 Inhibitors